The Lampard Inquiry, which is investigating deaths of more than 2,000 mental health patients in Essex over a 24-year period, heard testimony regarding the scientific basis for Oxevision technology deployment across the NHS.
Two University of Oxford experts presented findings from their review of 45 studies that had been cited to support the introduction of Oxevision monitoring systems. The academics identified significant limitations in the research base, noting that some studies involved employees of Oxevision or lacked sufficient scope. Their conclusion stated the studies did “not provide strong independent evidence of improved patient safety, acceptability or cost effectiveness.” One expert noted, however, that conducting ideal randomized controlled trials within mental health ward environments would present practical challenges.
Oxevision operates a monitoring system that uses infrared sensors and cameras to observe patients in their rooms. The company stated that the technology has had “significant” impact, noting that in one trust alone it assisted staff in responding to 1,453 safety incidents over a four-year period. The company emphasized that the mental health sector previously lacked dedicated medical device technology of this type.
Legal representatives and advocacy groups expressed concerns about the findings. Nina Ali, a partner at Hodge Jones & Allen, which represents more than 120 bereaved families at the inquiry, stated the expert testimony demonstrated an absence of clear evidence supporting improved patient safety or care. Stop Oxevision, a campaign group opposing the technology’s use, indicated the findings highlighted broader regulatory concerns, suggesting that technologies without robust independent evidence bases could be deployed widely without sufficient oversight.
The University of Oxford experts recommended that further independent, randomized, and adequately controlled research be conducted before stronger conclusions could be established regarding Oxevision. The inquiry will resume in October, when Baroness Lampard will consider whether to issue interim recommendations. Full hearings are scheduled to continue until late 2027, with a final report anticipated in 2028.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI